T1000	Negation 1321 1324	not
E1000	Negation:T1000 Scope:T1001
T1001	Span 1321 1503	not the T cell receptor-derived Type I pathway and possesses therapeutic potential for T cell-derived pathologies such as graft-versus-host disease, allergy, and autoimmune disorders
T1002	Speculation 469 478	suggested
E1001	Speculation:T1002 Scope:T1003
T1003	Span 469 569	suggested that JAK3 represents a pharmacological target to control certain lymphoid-derived diseases
T1004	Speculation 1244 1251	suggest
E1002	Speculation:T1004 Scope:T1005
T1005	Span 1244 1367	suggest that AG-490 inhibits the JAK3-mediated Type II signaling pathway but not the T cell receptor-derived Type I pathway
